Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs

Author： Avouac J   Allanore Y  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.9, Iss.7, 2008-05, pp. : 1121-1128

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Anti-TNF Treatment in Rheumatoid Arthritis

By  

Current Pharmaceutical Design, Vol. 17, Iss. 29, 2011-10 ,pp. : 3141-3151

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmacogenetics of anti-TNF treatment in patients with rheumatoid arthritis

By Coenen Marieke JH   Toonen Erik JM   Scheffer Hans   Radstake Timothy RDJ   Barrera Pilar   Franke Barbara  

Pharmacogenomics, Vol. 8, Iss. 7, 2007-07 ,pp. : 761-773

Future Medicine

Access to resources Recommend Favorite

Workplace impacts of anti-TNF therapies in rheumatoid arthritis: review of the literature

By Birnbaum Howard   Shi Lizheng   Pike Crystal   Kaufman Rebecca   Sun Peter   Cifaldi Mary  

Expert Opinion on Pharmacotherapy, Vol. 10, Iss. 2, 2009-02 ,pp. : 255-269

Informa Healthcare

Access to resources Recommend Favorite

Small Molecules as Anti-TNF Drugs

By  

Current Medicinal Chemistry, Vol. 22, Iss. 25, 2015-01 ,pp. : 2920-2942

Bentham Science Publishers

Access to resources Recommend Favorite

The Effects of Tumor Necrosis Factor Inhibitors on Cardiovascular Risk in Rheumatoid Arthritis

By  

Current Pharmaceutical Design, Vol. 18, Iss. 11, 2012-04 ,pp. : 1502-1511

Bentham Science Publishers

Access to resources Recommend Favorite